Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) plus Basal Insulin vs. GLP-1RA in Type 2 Diabetes Mellitus-A Systematic Review and Meta-analysis

被引：0
|
作者：
Satti, Muniza M.
O'Brien, Timothy
Liew, Aaron
机构：
来源：
DIABETES | 2018年 / 67卷
关键词：
D O I：
10.2337/db18-1108-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Glucagon-like peptide-1 receptor agonists (GLP1-RA) in the treatment of mitochondrial diabetes
    Maha Lebbar
    José Timsit
    Cédric Luyton
    Lucien Marchand
    Acta Diabetologica, 2021, 58 : 1281 - 1282
  • [32] Glucagon-like peptide-1 receptor agonists (GLP1-RA) in the treatment of mitochondrial diabetes
    Lebbar, Maha
    Timsit, Jose
    Luyton, Cedric
    Marchand, Lucien
    ACTA DIABETOLOGICA, 2021, 58 (09) : 1281 - 1282
  • [33] Efficacy and safety of the glucagon-like peptide-1 receptor agonist oral semaglutide in patients with type 2 diabetes mellitus: A systematic review and meta-analysis
    Li, Jingxin
    He, Ke
    Ge, Jun
    Li, Caixia
    Jing, Zeng
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2021, 172
  • [34] Efficacy and safety of basal insulin plus glucagon-like peptide-1 receptor agonist versus basal-bolus insulin in type 2 diabetes: A systematic review and meta-analysis of randomised controlled trials
    Acharya, Y.
    Tangney, N.
    Lim, J. L.
    O'Brien, T.
    Liew, A.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2021, 190 (SUPPL 3) : 110 - 110
  • [35] ARTIFICIAL INTELLIGENCE ANALYSIS OF SOCIAL MEDIA POSTS ON GLUCAGON-LIKE-PEPTIDE-1 RECEPTOR AGONISTS (GLP-1RA)
    Javaid, Aamir
    Baviriseaty, Sruthika
    Kukreja, Harshita
    Kim, Chang
    Martin, Seth Shay
    Marvel, Francoise
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 83 (13) : 2683 - 2683
  • [36] Health Care Utilization and Cost with Empagliflozin vs. GLP-1RA in Patients with Type 2 Diabetes
    Htoo, Phyo T.
    Tesfaye, Helen
    Wexler, Deborah J.
    Glynn, Robert
    Schmedt, Niklas
    Koeneman, Lisette
    Paik, Julie M.
    Patorno, Elisabetta
    DIABETES, 2024, 73
  • [37] Efficacy of HbA1c Changes, Weight Changes, and Blood Pressure Changes in GLP-1RA Daily Treatment or GLP-1RA Weekly Treatment in Type 2 Diabetes
    Cai, Xiaoling
    Yang, Wenjia
    Zhang, Simin
    Ji, Linong
    DIABETES, 2019, 68
  • [38] The Clinical Efficacy and Safety of Glucagon-Like Peptide-1 (GLP-1) Agonists in Adults with Type 2 Diabetes Mellitus
    Brice, Kira R.
    Tzefos, Maria K.
    CLINICAL MEDICINE INSIGHTS-ENDOCRINOLOGY AND DIABETES, 2011, 4 : 13 - 24
  • [39] Fixed-Ratio Combinations of Basal Insulin and GLP-1RA in the Management of Type 2 Diabetes Mellitus: Highlights from the Literature
    Lisco, Giuseppe
    De Tullio, Anna
    Guastamacchia, Edoardo
    Triggiani, Vincenzo
    ENDOCRINE METABOLIC & IMMUNE DISORDERS-DRUG TARGETS, 2021, 21 (04) : 626 - 646
  • [40] Glucagon-like peptide-1 receptor agonist and basal insulin combination tre atment for the management of type 2 diabetes: a systematic review and meta-analysis
    Eng, Conrad
    Kramer, Caroline K.
    Zinman, Bernard
    Retnakaran, Ravi
    LANCET, 2014, 384 (9961): : 2228 - 2234
12345